← Leaderboards
Meser M. Ali
Henry Ford Health System
$3,713,340
Attributed
$3,713,340
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $511.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,713,340 · 4
By mechanism
R01$2,870,971 · 2
K25$517,504 · 1
R21$324,865 · 1
Top collaborators
No co-investigators on record.
Most similar at Henry Ford Health System
Same institution · by research overlap
- James R Ewing$4,992,794
- Stephen L. Brown$3,235,934
- Robert A Knight$2,441,174
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorCancer TherapyExtracellularMagnetic Resonance ImagingMonitorTissuesDiagnosisMolecularOutcome ForecastClinical ApplicationNanoparticleNanosizedNeoplasm MetastasisPublic Health RelevanceBrain NeoplasmsMalignant GliomaDendrimersBlood VesselsGrowthAngiogenesisBaseChemotherapyGlioma
Grant awards (14)
Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in Glioblastoma$511,948
R01 · FY2025 · CA · contact PI
Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in Glioblastoma$447,809
R01 · FY2024 · CA · contact PI
Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in Glioblastoma$49,006
R01 · FY2024 · CA · contact PI
Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in Glioblastoma$499,464
R01 · FY2023 · CA · contact PI
Treatment of glioma with nanocombretastatin with MRI monitoring$333,940
R01 · FY2019 · CA · contact PI
Treatment of glioma with nanocombretastatin with MRI monitoring$344,269
R01 · FY2018 · CA · contact PI
Treatment of glioma with nanocombretastatin with MRI monitoring$342,554
R01 · FY2017 · CA · contact PI
Treatment of glioma with nanocombretastatin with MRI monitoring$341,981
R01 · FY2016 · CA · contact PI
Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes$131,282
K25 · FY2012 · CA · contact PI
Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes$131,282
K25 · FY2011 · CA · contact PI
MR Imaging of pHe and Chemotherapeutic Response in a Rat Glioma$178,964
R21 · FY2010 · NS · contact PI
Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes$128,715
K25 · FY2010 · CA · contact PI
MR Imaging of pHe and Chemotherapeutic Response in a Rat Glioma$145,901
R21 · FY2009 · NS · contact PI
Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes$126,225
K25 · FY2009 · CA · contact PI